Abstract
Circulating neuron-specific enolase (NSE) and chromogranin A (CgA) were measured in 128 patients with neuroendocrine tumours (NET) to compare their sensitivity and specificity, to investigate factors associated with elevated serum levels and to determine the usefulness of these markers in the follow-up of NET patients. NSE (Cispack NSE, Cis Bio International, Gif-sur-Yvette, France; normal <12.5 microg l(-1)), and chromogranin A (CgA-Riact, Cis Bio International, normal <100 microg l(-1)) were measured in 128 patients without renal insufficiency. There were 99 patients with gastroenteropancreatic (GEP) NET, 19 with medullary thyroid carcinoma and ten with phaeochromocytoma. Fifty-three patients with non-NET were studied as controls. Serum NSE and CgA levels were elevated in 48 (38%) and 76 (59%) of the 128 NET patients respectively. In all groups of NET patients, CgA proved to be more sensitive than NSE. NSE and CgA had a specificity of 73% and 68% respectively. Immunostaining for NSE was positive in three out of eight controls with elevated CgA levels, whereas immunostaining for CgA and synaptophysin was negative in all cases. Elevated CgA levels were significantly associated with two independent parameters, namely the presence of other secretions (P = 0.0001) and a heavy tumour burden (P = 0.001). Elevated NSE levels were exclusively associated with poor tumour differentiation (P = 0.01). Among six patients with NET followed for 11-37 months, CgA appeared to be a better marker of tumour evolution than NSE. We suggest that CgA ought to be the only general marker screened in NET patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baudin, E., Gigliotti, A., Ducreux, M. et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 78, 1102–1107 (1998). https://doi.org/10.1038/bjc.1998.635
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.635
This article is cited by
-
The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective
Current Treatment Options in Oncology (2023)
-
SOX11 is a sensitive and specific marker for pulmonary high-grade neuroendocrine tumors
Diagnostic Pathology (2022)
-
Prediction of Outcome After Endovascular Embolectomy in Anterior Circulation Stroke Using Biomarkers
Translational Stroke Research (2022)
-
Role of biomarker tests for diagnosis of neuroendocrine tumours
Nature Reviews Endocrinology (2018)
-
Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers
Scientific Reports (2017)